On 3/31/25, Catalyst Biosciences Inc (NASDAQ: GYRE) stock suffered a major decline of -15.3%, closing at $7.72. Moreover, trading volume in this decline was exceptionally high at 326% of normal. Relative to the market the […]
Biolife Solutions Inc (NASDAQ: BLFS) stock suffered a major decline of -12.0% on 3/31/25. The shares closed at $22.84. Moreover, exceptionally high trading volume at 343% of normal accompanied the decline. The stock has been […]
Advanced Emissions Solutions Inc (NASDAQ: ARQ) suffers from exceptional negative changes in investment behavior: negative upside/downside volume developed, and the stock fell on very heavy volume. Advanced Emissions Solutions Inc (NASDAQ: ARQ) suffers from notable […]
Recent exceptional negative changes in investment behavior have affected AGCO Corp (NYSE: AGCO): negative upside/downside volume developed, and its shorter term price trend turned down. AGCO Corp (NYSE: AGCO) suffers from meaningful negative changes in […]
Stock Rating Upgrade Reflecting improving fundamentals and high Appreciation Potential, the Value Trend Rating for Wave Life Sciences Ltd (NASDAQ: WVE) improved in the last week. WVE’s current Value Trend Rating is C and the […]
Stock Rating Downgrade During the last several trading days the Value Trend Rating for Universal Insurance Holdings (NYSE: UVE) weakened from B to C reflecting eroding fundamentals and low Appreciation Potential. Recent Price Action Universal […]
Stock Rating Downgrade During the last several trading days the Value Trend Rating for The Middleby Corp (NASDAQ: MIDD) weakened from B to C reflecting eroding fundamentals and low Appreciation Potential. Recent Price Action The […]
Stock Rating Downgrade Reflecting eroding fundamentals and low Appreciation Potential, the Value Trend Rating for Summit Midstream Partners LP (NYSE: SMC) weakened during the last several trading days. SMC’s current Value Trend Rating is C […]
Recent meaningful negative changes in fundamentals have affected Sleep Number Corp (NASDAQ: SNBR): the stock’s power rating fell below 50, significant quarterly earnings deceleration occurred, and significant quarterly sales deceleration occurred. Important negative changes in […]
Stock Rating Upgrade Reflecting improving fundamentals and high Appreciation Potential, the Value Trend Rating for Regeneron Pharmaceuticals Inc (NASDAQ: REGN) improved in recent days. REGN’s current Value Trend Rating is C and the prior Rating […]
Privacy Statement Terms Of Use ©2024 PriceTarget Research